Under construction – not a live service
Sign in
Enrolling by invitationPhase 2

Bronchial artery chemoembolization plus drug therapy for advanced non-small cell lung cancer

Tests bronchial artery chemoembolization with drugs in adults with advanced non-small cell lung cancer.

Key facts

Who runs it
Fujian Cancer Hospital
Where
Fuzhou, ChinaSee the site
Trial code
Registry title
Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
Status
Enrolling by invitation
Phase
Phase 2
People taking part
20 people, planned
Started
9 Apr 2026
Expected to end
30 Oct 2028
Type of study
Interventional
Treatments tested
  • Bronchial Arterial Chemoembolization (BACE)
  • Systemic anti-tumor combination medications
Record updated
31 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced non-small cell lung cancer who have no standard treatment left. Their lung tumor must be treatable by delivering chemotherapy into the tumor's own arteries.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Advanced non-small cell lung cancer confirmed by tissue examination, with at least one tumor that can be measured on scans (RECIST 1.1). ECOG performance status 0-2. The lung tumor must be treatable by bronchial arterial chemoembolization, as judged by interventional radiology specialists.
Earlier treatment
Without a driver gene change: the cancer grew or treatment was not tolerated after platinum-based double chemotherapy plus a PD-1/PD-L1 immune checkpoint inhibitor. With a driver gene mutation (for example EGFR, ALK): the cancer grew or side effects were unacceptable after the matching targeted therapy plus at least one line of systemic chemotherapy.
Biomarker or test result
Either no driver gene change, or a positive driver gene mutation such as EGFR or ALK.

Main reasons for not taking part

  • Mixed small cell lung cancer component
  • Active bleeding or blood clotting disorder
  • Severe allergy to contrast dye, chemotherapy drugs or the study medicines
  • Extensive and fast-growing spread of cancer inside or outside the lungs
  • Expected survival of less than 3 months

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age between 18 and 75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
  • Histopathologically confirmed advanced non-small cell lung cancer (NSCLC), with at least one measurable target lesion defined by RECIST Version 1.1
  • Two eligible patient subgroups:; Patients with negative driver gene alterations: experienced disease progression or intolerable toxicity after platinum-based doublet chemotherapy combined with PD-1/PD-L1 immune checkpoint inhibitors; Patients with positive driver gene mutations (e.g., EGFR, ALK): experienced disease progression or unacceptable adverse reactions after corresponding targeted therapy plus at least one line of systemic chemotherapy
  • Target lung lesions are suitable for bronchial arterial chemoembolization (BACE), as assessed by interventional radiology specialists
  • Adequate function of major vital organs
  • Able to provide written informed consent prior to any study-related procedures

Who cannot take part

  • Histopathological confirmation of mixed small cell lung cancer components
  • Active bleeding or coagulation disorders
  • Severe hypersensitivity to contrast media, chemotherapeutic agents, or combined study medications
  • Severe pre-existing hepatic, renal, cardiac, or pulmonary dysfunction
  • Extensive and rapidly progressive intra-pulmonary or extra-pulmonary metastatic lesions
  • Angiography during the procedure shows that superselective catheterization cannot completely avoid hazardous blood vessels such as spinal arteries
  • Estimated survival time less than 3 months

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in China

  • Fujian Cancer HospitalFuzhou, ChinaNo longer taking part

About the trial

What the trial wants to find out

Patients with advanced non-small cell lung cancer (NSCLC) who experience disease progression after standard systemic therapies or are unable to tolerate such therapies have limited subsequent treatment options. Bronchial arterial chemoembolization (BACE) is a locoregional interventional procedure that delivers chemotherapeutic agents directly into tumor-feeding bronchial arteries, followed by arterial embolization, with the aim of increasing local drug exposure and reducing tumor blood supply.

Read full original descriptionShow less

This prospective, open-label, single-arm Phase II study will evaluate the efficacy and safety of BACE-based combination therapy in adult patients with advanced NSCLC who have no remaining standard treatment options and whose target intrathoracic lesions are considered suitable for BACE. Approximately 20 eligible participants are planned for enrollment between April 2026 and April 2028.

All enrolled participants will receive protocol-specified BACE in combination with systemic anti-tumor therapy. Treatment selection and administration will be performed according to the study protocol, taking into account the participant's molecular characteristics, prior treatments, clinical condition, and treatment tolerance.

The study will primarily assess local tumor control and the safety of the combined treatment strategy. Tumor response and disease progression will be evaluated by contrast-enhanced imaging according to RECIST criteria, and adverse events will be assessed using CTCAE Version 5.0. Additional assessments will include objective tumor response, disease control, progression-free survival, and overall survival.

Exploratory analyses will investigate the systemic pharmacokinetics of chemotherapeutic agents administered during BACE and potential treatment-related changes in the tumor immune microenvironment.

The group in the trial

  • Bronchial Arterial Chemoembolization (BACE) Combined Anti-Tumor Therapy ArmTreatment being tested

    This is an open-label, prospective single-arm Phase II clinical trial. It aims to evaluate the efficacy and safety of bronchial arterial chemoembolization (BACE) combination therapy in adult patients with advanced non-small cell lung cancer (NSCLC) who have no standard treatment options left.

    Treatment: Bronchial Arterial Chemoembolization (BACE) and Systemic anti-tumor combination medications

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Single-Arm Phase II Study of Bronchial Artery Chemoembolization (BACE) Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Without Standard Treatment Options
Plain-language title
Bronchial artery chemoembolization plus drug therapy for advanced non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07738367, who can take part
Record updated
31 July 2026